The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C

Seminars in Liver Disease

Volumn 19, Issue 1 SUPPL. 1, 1999, Pages 95-102

  Younossi, Zobair M ^a   Perrillo, Robert P ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Amantadine; Interferon alfa 2b; Nonsteroidal anti inflammatory drugs; Ribavirin; Rimantadine; Ursodeoxycholic acid

Indexed keywords

ALPHA2B INTERFERON; AMANTADINE; NONSTEROID ANTIINFLAMMATORY AGENT; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

CHEMICAL STRUCTURE; CONVULSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECZEMA; FATIGUE; HEPATITIS C; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0032898676     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Poynard T, Leroy V, Mathurin P, Cohard M, Opolon P, Zarski JP. Treatment of chronic hepatitis C by interferon for longer duration than six months. Dig Dis Sci 1996;41(suppl 12):99S-102S
2. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis [published erratum appears in N Engl J Med 1996;334:1143]. N Engl J Med 1995;332: 1457-1462
3. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997;26(suppl 1, pt3):83S-88S
4. Mycek MJ, Harvey RA, Champe PC, eds. Lippincott's Illustrated Reviews: Pharmacology. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1992
5. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997;42:1681-1687
6. Fang JC, Hespenheid E, Driscoll C, Caldwell S. Amantadine HCL treatment of chronic hepatitis C [abstract]. Hepatology 1997;26:217A. Abstract 356
7. Olmeda M, Khalili M, Perrillo RP. Amantadine monotherapy in patients with chronic hepatitis C [abstract]. Gastroenterology 1998;114:A1316. Abstract L0484
8. Tong M, Blatt LM, Conrad A, Leong S. Treatment of chronic HCV infection with rimantadine shows no biochemical or virological benefit in patients who have previously failed interferon-alpha therapy [abstract]. Hepatology 1997;26:218A. Abstract 357
9. Brillanti S, Foli M, Gramantieri L, Di Tomaso M, Masci C, Bolondi L. Triple antiviral therapy for chronic hepatitis C in interferon alfa non-responders: a pilot randomized controlled study [abstract]. Hepatology 1997;26:367A. Abstract 953
10. Pimstone N, Yu A, Akhondi M, Lumbra L. End-of-treatment response of chronic hepatitis with either amantadine or rimantadine [abstract]. Hepatology 1997;26:A217. Abstract 355
11. Kwo P, Fields S, Born L, et al. An open label trial of rimantadine for treatment of patients who have failed or are unable to tolerate interferon therapy for hepatitis C [abstract]. Gastroenterology 1998;114:A1281. Abstract L0344
12. Mangia A, Facciorusso D, Lezzi G, et al. Amantadine in HCV chronic infection: a 6 months follow up study [abstract]. J Hepatol 1998;28:105. Abstract P/C05/D45
13. Wiley TE, Mihalov M, O'Riordan K. Layden TJ, Lam NP. Amantadine is not effective in clearing HCV from the serum in patients who are not candidates for interferon therapy [abstract]. Gastroenterology 1998;114:A1365. Abstract L0686
14. Findor JA, Daurich JR, Igartua E, et al. Amantadine HCL alone and associated with recombinant alpha IFN 2a during a short term therapy in chronic HCV infection [abstract]. Hepatology 1997;26:217A. Abstract 354
15. Khalili M, Olmeda M, Denham CB, Perrillo RP. A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non-responders with chronic hepatitis C [abstract]. Hepatology 1998;28:169A. Abstract 26
16. Younossi ZM, Mullen K, Zakko W, et al. Interferon α2b and ribavirin vs interferon α2b and amantadine for chronic hepatitis C (non-responder): a multi-center, randomized, double-blind trial [abstract]. Hepatology 1998;28:284A. Abstract 487
17. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother 1995;29:299-310
18. Takano S, Ito Y, Yokosuka O, et al. A multiccnter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20:558-564
19. Boucher E, Jouanolle H, Andre P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995;21:322-327
20. Angelico M, Gandin C, Pescarmona E, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995;90:263-269
21. Senturk H, Uzunalimoglu O, Batur Y, et al. Long-term efficacy of interferon-α and ursodeoxycholic acid in treatment of chronic type C hepatitis. Dig Dis Sci 1997;42:1438-1444
22. Clerici C, Distrutti E, Gentili G, et al. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis. Minerva Med 1997;88:219-225
23. Tanaka K, Kondo M, Sakaguchi T, et al. Efficacy of ursodeoxycholic acid in combination with interferon-α in treating chronic hepatitis C: results of a long-term follow-up trial. J Gastroenterol Hepatol 1996;11:1155-1160
24. Kiso S, Kawata S, Imai Y, et al. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels. J Gastroenterol 1996; 31:75-80
25. Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. Eur J Gastroenterol Hepatol 1995;7:151-154
26. Mohler M, Seipp S, Tox U, Stremmel W, Theilmann L, Goeser T. Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C. Dig Dis Sci 1996;41:1276-1277
27. Lu CL, Chan CY, Hwang SJ, Lu RH, Lee SD. Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:432-437
28. Andreone P, Cursaro C, Gasbarrini G. Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 1993;19:228-231
29. Zarski JP, Maynard-Muet M, Chousterman S, et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology 1998;27:862-867
30. Anderson FH, Zeng L, Yoshida EM, Rock NR. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Can J Gastroenterol 1997; 11:294-297
31. Heinrich D, Maier KP. [Treatment of chronic virus hepatitis with acetylsalicylic acid]. Schweiz Med Wochenschr 1995; 125: 755-757
32. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26 (suppl 1, pt3):62S-65S